相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
Naval Daver et al.
BLOOD (2022)
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial
Charlotte M. Niemeyer et al.
BLOOD ADVANCES (2021)
Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation
Nao Yoshida et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Prospects for Venetoclax in Myelodysplastic Syndromes
Jacqueline S. Garcia
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia
Amanda C. Winters et al.
PEDIATRIC BLOOD & CANCER (2020)
Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era
Sanghee Hong et al.
Hematology/ Oncology and Stem Cell Therapy (2020)
Therapeutic modulation of the CD47-SIRP alpha axis in the pediatric tumor microenvironment: working up an appetite
Ajay Gupta et al.
CANCER DRUG RESISTANCE (2020)
Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA
Brian J. Ball et al.
BLOOD (2019)
How I treat myelodysplastic syndromes of childhood
Franco Locatelli et al.
BLOOD (2018)
Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants
V. Pastor et al.
LEUKEMIA (2017)
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
Daniel B. Lipka et al.
NATURE COMMUNICATIONS (2017)
Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents
Marcin W. Wlodarski et al.
BLOOD (2016)
Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group
Annamaria M. Cseh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Myelodysplastic and myeloproliferative disorders of childhood
Henrik Hasle
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group
Annamaria Cseh et al.
BLOOD (2015)
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study
B. Strahm et al.
LEUKEMIA (2011)
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis
Ronit Gurion et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium
Rebecca J. Chan et al.
LEUKEMIA RESEARCH (2009)
Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk Myelodysplastic syndrome (MDS): Update including extended treatment
Hagop Kantarjian et al.
BLOOD (2007)
Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia
A. Yoshimi et al.
LEUKEMIA (2007)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes
E Kaminskas et al.
CLINICAL CANCER RESEARCH (2005)
Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes
G Marcucci et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial
F Locatelli et al.
BLOOD (2005)
Second allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia: Case report and literature review
YH Chang et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2004)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
